Talis Biomedical (TLIS) has released an update to notify the public and investors about its officers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Talis Biomedical Corporation, following its strategic reevaluation and a significant workforce reduction, has terminated the role of Dr. Andrew Lukowiak as President and Chief Scientific Officer, effective January 14, 2024. This action is not due to any operational, policy, or accounting disagreements, and the company has no plans to appoint a successor for the position.
For further insights into TLIS corporate activity, check out TipRanks’ Insiders Trading Activity page.